Search Results - Christine A. Pratilas

Refine Results
  1. 1
    Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

    Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response by Christine A. Pratilas, David B. Solit

    Published 2010
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Targeting Oncogenic BRAF in Human Cancer

    Targeting Oncogenic BRAF in Human Cancer by Christine A. Pratilas, Feng Xing, David B. Solit

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor

    From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor by Kathryn M. Lemberg, Jiawan Wang, Christine A. Pratilas

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors

    BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors by Karisa C. Schreck, Stuart A. Grossman, Christine A. Pratilas

    Published 2019
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    <sup>V600E</sup> BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway

    <sup>V600E</sup> BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway by Christine A. Pratilas, Barry S. Taylor, Qing Ye, Agnès Viale, Chris Sander, David B. Solit, Neal Rosen

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance

    Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance by Grazia Ambrosini, Christine A. Pratilas, Li-Xuan Qin, Madhavi Tadi, Oliver Surriga, Richard D. Carvajal, Gary K. Schwartz

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Models from experiments: combinatorial drug perturbations of cancer cells

    Models from experiments: combinatorial drug perturbations of cancer cells by Sven Nelander, Weiqing Wang, Bengt‐Olof Nilsson, Qing‐Bai She, Christine A. Pratilas, Neal Rosen, Peter Gennemark, Chris Sander

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors

    Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors by Jiawan Wang, Kai Pollard, Amy N. Allen, Tushar Tomar, Dirk Pijnenburg, Zhan Yao, Fausto J. Rodríguez, Christine A. Pratilas

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Integrated molecular and clinical analysis of BRAF-mutant glioma in adults

    Integrated molecular and clinical analysis of BRAF-mutant glioma in adults by Karisa C. Schreck, Pinky Langat, Varun Bhave, Taibo Li, E. L. Woodward, Christine A. Pratilas, Charles G. Eberhart, Wenya Linda Bi

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Relapse-free survival in a pediatric patient with recurrent EZH2-mutant melanoma treated with adjuvant tazemetostat

    Relapse-free survival in a pediatric patient with recurrent EZH2-mutant melanoma treated with adjuvant tazemetostat by Erin E. Resch, Stavriani C. Makri, Paola Ghanem, Ezra Baraban, Kenneth J. Cohen, Alan R. Cohen, Evan J. Lipson, Christine A. Pratilas

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines

    BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines by Rébecca Leboeuf, Jacqueline E. Baumgartner, Miriam Benezra, Roberta Malaguarnera, David B. Solit, Christine A. Pratilas, Neal Rosen, Jeffrey A. Knauf, James A. Fagin

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition

    3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition by David B. Solit, Elmer Santos, Christine A. Pratilas, Jose Lobo, Maxim A. Moroz, Shangde Cai, Ronald Blasberg, Judith S. Sebolt‐Leopold, Steven M. Larson, Neal Rosen

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i>-Mutant Lung Cancer

    Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i>-Mutant Lung Cancer by Erin M. Tricker, Chunxiao Xu, Sharmeen Uddin, Marzia Capelletti, Dalia Ercan, Atsuko Ogino, Christine A. Pratilas, Neal Rosen, Nathanael S. Gray, Kwok‐Kin Wong, Pasi A. Jänne

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies

    Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies by J. Kyle Bruner, S. Hayley, Li Li, Alice Can Ran Qin, Michelle A. Rudek, Richard J. Jones, Mark J. Levis, Keith W. Pratz, Christine A. Pratilas, Donald Small

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Novel PAX3::MAML3 fusion identified in alveolar rhabdomyosarcoma, using DNA methylation profiling to expand the genetic spectrum of “fusion-positive” cases

    Novel PAX3::MAML3 fusion identified in alveolar rhabdomyosarcoma, using DNA methylation profiling to expand the genetic spectrum of “fusion-positive” cases by Josephine K. Dermawan, Faizan Malik, John Gross, Ezra Baraban, Christine A. Pratilas, Wadad Mneimneh, Matteo Trucco, Wenyue Sun, Frederic G. Barr, Felipe D’Almeida Costa, Karen Fritchie

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells

    Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells by Anil Korkut, Weiqing Wang, Emek Demir, Bülent Arman Aksoy, Xiaohong Jing, Evan Molinelli, Özgün Babur, Debra L. Bemis, S. Onur Sumer, David B. Solit, Christine A. Pratilas, Chris Sander

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Size-based detection of sarcoma circulating tumor cells and cell clusters

    Size-based detection of sarcoma circulating tumor cells and cell clusters by Masanori Hayashi, Peixuan Zhu, Gregory McCarty, Christian F. Meyer, Christine A. Pratilas, Adam S. Levin, Carol D. Morris, Catherine M. Albert, Kyle W. Jackson, Cha-Mei Tang, David M. Loeb

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations

    Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations by Doreen N. Palsgrove, Yunjie Li, Christine A. Pratilas, Ming‐Tseh Lin, Aparna Pallavajjalla, Christopher D. Gocke, Angelo M. De Marzo, Andrés Matoso, George J. Netto, Jonathan I. Epstein, Pedram Argani

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    BRAF mutation predicts sensitivity to MEK inhibition

    BRAF mutation predicts sensitivity to MEK inhibition by David B. Solit, Levi A. Garraway, Christine A. Pratilas, Ayana Sawai, Gad Getz, Andrea Basso, Qing Ye, Jose Lobo, Yuhong She, Iman Osman, Todd R. Golub, Judith S. Sebolt‐Leopold, William R. Sellers, Neal Rosen

    Published 2005
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

    The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner by Eric W. Joseph, Christine A. Pratilas, Poulikos I. Poulikakos, Madhavi Tadi, Weiqing Wang, Barry S. Taylor, Ensar Halilovic, Yogindra Persaud, Feng Xing, Agnès Viale, James Tsai, Paul B. Chapman, Gideon Bollag, David B. Solit, Neal Rosen

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: